Abstract
Ribavirin antagonizes the in vitro anti-hepatitis C virus (HCV) activity of the pyrimidine nucleoside analogue 2'-C-methylcytidine, the active component of the experimental anti-HCV drug valopicitabine. In contrast, the combination of ribavirin with either the purine nucleoside analogue 2'-C-methyladenosine or the HCV protease inhibitor VX-950 resulted in an additive antiviral activity. These findings may have implications when planning clinical studies with valopicitabine.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antiviral Agents / antagonists & inhibitors*
-
Antiviral Agents / chemistry
-
Antiviral Agents / pharmacology*
-
Cell Line, Tumor
-
Cytidine / analogs & derivatives*
-
Cytidine / antagonists & inhibitors
-
Drug Antagonism
-
Drug Therapy, Combination
-
Hepacivirus / drug effects*
-
Hepacivirus / physiology
-
Humans
-
Ribavirin / pharmacology*
-
Virus Replication / drug effects
Substances
-
Antiviral Agents
-
2'-C-methylcytidine
-
Ribavirin
-
Cytidine